Mohammad Hoque

Medicine & Life Sciences

1. Methylation 100%
2. Neoplasms 50%
3. Genes 37%
4. Epigenomics 33%
5. Urinary Bladder Neoplasms 31%
6. Carcinoma 28%
7. Non-Small Cell Lung Carcinoma 27%
8. Lung Neoplasms 26%
9. Prostatic Neoplasms 24%
10. Squamous Cell Carcinoma of Head and Neck 23%
11. Tumor Suppressor Genes 20%
12. Polymerase Chain Reaction 20%
13. Urine 19%
14. Head and Neck Neoplasms 19%
15. Cell Line 18%
16. Mutation 17%
17. Biomarkers 16%
18. Urinary Bladder 16%
19. DNA 16%
20. Neoplastic Stem Cells 16%
21. Squamous Cell Carcinoma 16%
22. Prostate 14%
23. Carcinogenesis 13%
24. Genome 12%
25. MicroRNAs 12%
26. Salivary Glands 11%
27. Growth 10%
28. DNA Methylation 10%
29. Mitochondrial DNA 9%
30. Prostatic Intraepithelial Neoplasia 9%
31. Recurrence 9%
32. Adenocarcinoma of Lung 9%
33. Aquaporin 1 9%
34. Drug Therapy 9%
35. Mouth Neoplasms 8%
36. Single Nucleotide Polymorphism 8%
37. Cisplatin 8%
38. Messenger RNA 8%
39. Biopsy 8%
40. Apoptosis 8%
41. Tissue Inhibitor of Metalloproteinase-3 8%
42. Loss of Heterozygosity 8%
43. Heterografts 7%
44. Aquaporins 7%
45. ErbB Receptors 7%
46. Lung 7%
47. Adenocarcinoma 7%
48. Clone Cells 7%
49. CpG Islands 7%